The emerging international biomedical law tends to recognise the right not to know one’s genetic status. However, the basis and conditions for the exercise of this right remain unclear in domestic laws. In addition to this, such a right has been criticised at the theoretical level as being in contradiction with patient’s autonomy, with doctors’ duty to inform patients, and with solidarity with family members. This happens especially when non-disclosure poses a risk of serious harm to the patient’s relatives who, without that vital information, could be deprived of preventive or therapeutic measures. This paper argues, firstly, that individuals may have a legitimate interest in not knowing their genetic make up to avoid serious psychological consequences; secondly, that this interest, far from being contrary to autonomy, may constitute an enhancement of autonomy; thirdly, that the right not to know cannot be presumed, but must be “activated” by the individual’s explicit choice, and fourthly, that this is not an absolute right, in the sense that it may be restricted when disclosure to the patient is necessary in order to avoid a risk of serious harm to third persons.

The claim for a “right not to know” might sound strange. Over the last decades it has been strongly stressed that the patient has the right to be informed about the risks and benefits of a treatment or intervention and, on this basis, to consent—or not—to them. Having affirmed the patient’s “right to know” as a fundamental ethical and legal principle, we are now faced with the apparently opposite demand. This takes place particularly in the field of genetics: as the predictive power of genetic tests increases, more and more people come to know that they are at risk from a serious disease with no real chance of reducing that risk or of obtaining an effective treatment. To illustrate the problem, let us consider the following examples:

- Barbara, a 35 year old woman and mother of two children, has a family history of breast cancer. Urged by her relatives, she decided to undergo the BCRA1/2 testing. If Barbara has the mutation, she has 80% risk of developing breast cancer. Three days later, depressed by the difficult decisions she would have to make in case the mutation was found, she asked the doctor not to inform her about the test results.

- Peter, a 29 year old married man, is invited to participate in a research study about the mutations that may cause Alzheimer’s disease (the most common cause of dementia) because a member of his family has been diagnosed with this disorder. DNA samples will be coded, but the unit’s director will keep a confidential list of the names of each participant. Although this is a research study and not a clinical genetic test, the laboratory offers Peter the opportunity to be informed about the result of the analysis, in case it indicates the presence of a mutation. This information may be helpful in predicting his risk of developing Alzheimer’s disease or of having children with this disorder. However, Peter does not want to know the results and therefore does not sign the request to be informed.

Far from being purely academic, both scenarios happen in the daily routine of genetic testing and research. In order to understand the refusal of Anne and Peter to have access to their genetic information, one has to consider that the burden of knowledge may become unbearable for them, leading to a severe psychological depression and having a negative impact on their family life and on their social relationships in general. For many people, the discovery that they have a genetic condition that places them at a high risk of suffering certain untreatable diseases could so depress them that the quality, joy, and purpose of their lives would literally evaporate. Now, in such situations, “it may not be justifiable to take away hope from a person by exposing them to knowledge they do not want”. Therefore, it seems reasonable to allow these people to choose not to receive that potentially harmful information and to continue their lives in peace.

This paper argues that “autonomy”, understood in a wide sense, provides a theoretical basis for a right not to know one’s genetic status. The discussion will focus on predictive testing of adults, and not on other types of genetic testing (diagnostic testing, preimplantation genetic diagnosis, prenatal testing, and newborn screening), which raise other specific ethical issues. It is also worth mentioning here that, although the interest in not knowing may be greater in the case of single gene disorders (when a particular mutation is causally sufficient for a disease to occur) than in polygenic disorders, it is not the purpose of this paper to enter into a detailed discussion of the issues raised by each type of genetic testing. Rather, what is intended is to provide a broad philosophical and legal analysis of the debate regarding the right not to know one’s genetic status.
After summarising the objections made against the right not to know (1), it will be recalled that various recent ethical and legal instruments explicitly recognise this claim (2). Then, this paper will attempt to respond to those objections (3), and will suggest some conditions that should be fulfilled for the exercise of the right not to know (4).

OBJECTIONS TO THE RIGHT NOT TO KNOW

Several criticisms have been formulated against the formal recognition of a right not to know one’s genetic status. The main practical objection is that this right is not feasible because, in order to decide not to receive some information, the person should previously be informed of the possibility of having a particular health risk. Now, this is precisely what the individual wanted to avoid.

A most fundamental objection is that, according to a long and well established philosophical tradition, knowledge is always good in itself and therefore a “right to remain in ignorance” appears as a contradiction; that is, as an irrational attitude, which is incompatible with the notion of “right”.

Let us recall that, according to Aristotle “all men by nature desire to know” and this desire is one of the features that distinguishes humans from other animals. The Enlightenment’s philosophers considered also human progress in direct connection with an increasing access to knowledge. In the words of Kant, “Habe courage to use your own understanding!” was indeed the motto of the Enlightenment. Adopting this latter perspective, a contemporary philosopher acidly criticises the recent international recognition of the right not to know as “directly opposed to human rights philosophy and to ethics”.

The right not to know would be also contrary to the recent evolution of the doctor-patient relationship, which tends to abandon the old paternalism that allowed the doctor not to tell the truth to the patient. Moreover, the claim not to know would be contrary to the doctor’s “duty to disclose” risks to patients. Therefore such a claim would represent a return to a paternalistic attitude given that it puts people in a state of ignorance, depriving them of choice.

For the same reason, the right not to know is criticised as being opposed to patients’ autonomy, given that the exercise of autonomy depends on the ability to understand relevant information and only on this basis to consent to treatment.

Another objection refers to the value of solidarity and responsibility for others: the individual who chooses not to know his or her genetic status—thereby putting him or herself in a position of being unable to disclose that vital information to family members—could be said to be acting against solidarity. The same thing could be said about an individual who refuses to participate in a population screening programme because of a claimed right not to know.

ETHICAL AND LEGAL RECOGNITION OF THE RIGHT NOT TO KNOW

In spite of the criticisms levelled against it, the right not to know has been explicitly recognised by various recent ethical and legal instruments relating to biomedical issues. The most impressive examples are probably the European Convention on Human Rights and Biomedicine and the UNESCO Universal Declaration on the Human Genome and Human Rights, both adopted in 1997. Article 10.2 of the European Convention states: “Everyone is entitled to know any information collected about his or her health. However, the wishes of individuals not to be so informed shall be observed”. The Explanatory Report to the Convention justifies the right not to know by saying that “patients may have their own reasons for not wishing to know about certain aspects of their health”. Similarly, the UNESCO Declaration on the Human Genome provides (in Article 5c) that: “The right of every individual to decide whether or not to be informed of the results of genetic examination and the resulting consequences should be respected”.

Other important international ethical guidelines also explicitly recognise the right not to know. According to the “Declaration on the Rights of the Patient” adopted by the World Medical Association in 1981 and amended in 1995, “the patient has the right not to be informed on his/her explicit request, unless required for the protection of another person’s life” (Article 7d). The WHO “Guidelines on Ethical Issues in Medical Genetics and the Provision of Genetic Services” (1997) states that “the wish of individuals and families not to know genetic information, including test results, should be respected, except in testing of newborn babies or children for treatable conditions” (see table 7 in these Guidelines).

It is important to note that in all the aforementioned international instruments, an explicit choice is necessary for the functioning of the right not to know: the European Convention refers to an individual’s “wishes”; the UNESCO Declaration mentions the individual’s “decision”; the WMA Declaration points out the necessity of an “explicit request” of the patient; the WHO Guidelines mention the “wishes” of individuals and their families.

At the national level, the right not to know is recognised by the French Law on Patients’ Rights, adopted in March 2002: “everyone has the right to be informed on his/her health status …. The person’s will to remain ignorant of diagnostic and prognostic information should be respected, except when third parties are exposed to a risk of transmission” (Article 1111-2, Public Health Code). Similar provisions can be found in the Dutch Medical Treatment Act of 1994 (Civil Code, Article 449), the Belgian Patient’s Rights Act of 2002 (Article 6), and the Hungarian Health Act of 1997 (Section 14.1).

In the United Kingdom, the former Human Genetics Advisory Commission (HGAC) recommended in its July 1999 report that “an individual’s ‘right not to know’ their genetic constitution should be upheld”. More recently, the current Human Genetics Commission (HGC) concluded in its report on the use of personal genetic data that “people have an ‘entitlement not to know’ genetic information about themselves”.

THE RIGHT NOT TO KNOW: AN EXPRESSION OF AUTONOMY

The main thesis of this paper is that the claim for not knowing one’s genetic status, far from being contrary to autonomy—understood as an individual’s self determination—may be indeed considered a legitimate expression of this basic bioethical principle. In other words, the choice of not knowing the results of genetic tests does not fall into a paternalistic attitude because the challenge to medical paternalism is precisely based on the idea that people should be free to make their own choices with respect to information. If we understand autonomy in this wider sense, then the decision not to know should be, at least in principle, as fully respected as the decision to know.

Thus, the possibility to choose not to know the results of genetic tests may constitute an enhancement of autonomy, because the decision to know or not to know is not taken out of the hands of the patient by the doctor. Precisely with this broad understanding of autonomy, the right not to know is widely recognised, for example, by the German legal literature as a part of the “right to informational self determination” (“Recht auf informationelle Selbstbestimmung””).
In addition to this, let us not forget that there is not an absolute “duty to disclose” information to patients, neither on legal nor on ethical grounds. On the contrary, it is the responsibility of the healthcare professional to assess the amount of information an individual wants and is able to deal with at a particular time.\textsuperscript{21}

If this understanding of autonomy is correct, it can be argued that the theoretical foundation of the right not to know lies on the respect for individual autonomy, even if the ultimate foundation of this right is the individual’s interest in not being psychologically harmed. Both grounds are indeed situated at a different level. Autonomy is the immediate source of the right not to know, but what is in the end protected is the psychological integrity of the person. Certainly, patients do not need to prove the harmful effects of genetic information, because each of them is entitled to recognize what information may be psychologically harmful. In any case, the recognition of the potentially negative effect of genetic information allows us to better understand what the right not to know tends to protect and what, ultimately, justifies this claim. We deal here with nothing more than the oldest principle of medical ethics: “first, do no harm” (\textit{Primum non nocere}), which is formulated in modern times in the so called “principle of non-maleficence” that certainly includes patient’s psychological integrity.\textsuperscript{22}

The criticism that the right not to know is contrary to the right of informed consent seems misplaced. The right to remain in ignorance about one’s genetic make up should not be mistaken for a waiver of informed consent. In the exercise of a waiver, a patient voluntary relinquishes the right to an informed consent and relieves the physician from the obligation to inform. It seems to be a consensus among ethicists that the acceptance of waivers of consent is a dangerous practice.\textsuperscript{23} But in the case of the right not to know the informed consent exists, insofar as the person is perfectly aware that he or she will be submitted to a genetic test that may indicate the risk of developing a disease. In this case, the individual just refuses to be informed of the test outcome. Thus, the ignorance does not concern the medical practice itself, for which a valid informed consent has been given, but only its result. Consequently, the individual does not receive any particular medical treatment on the basis of ignorance. A different situation may arise in the emerging area of pharmacogenetics. What if a patient arguing the right not to know refuses the test that can determine if a particular drug may have an adverse effect and in spite of that demands the medicine? In such a case the pharmacogenetic test, as far as it has been proved to be effective, should perhaps be considered as a part of the treatment itself. Therefore, it would be a breach of the physician’s duty of care to prescribe a drug for a patient who intends to use it without the test having been performed. In other words, in the absence of the test, the requirement of informed consent for the treatment would not be met. This conclusion is especially valid because information about drug response could hardly be considered contrary to the patient’s interests.

What about the argument that the right not to know is intrinsically not feasible because its exercise always requires a previous knowledge? Certainly, for the exercise of this right the person should have, at least, a general and abstract knowledge of the risk. We know that we are all at risk of developing genetic diseases, particularly when we have a family history of a particular genetic condition. But some risks may be so remote in our perception as to seem virtually inconceivable. In contrast, a genetic testing, which may determine individuals likely to suffer from a serious disorder or even the certainty that the disease will emerge (in the case of a single gene disorder), makes those vague concerns look much more real. This is precisely why an individual’s refusal to know the results of genetic tests might make sense.

One has to recognise however that the refusal to be informed about one’s genetic status may in some cases be problematic, because genetic information is not only an individual, but also a family affair. Tests results may alert family members about a serious risk, giving them the opportunity of changing their life plans, or eventually of preventing or treating a disease. The familial nature of genetic information has even led some ethicists to argue that the concept of “genetic privacy” is a contradiction in terms.\textsuperscript{24} In any case, the question is: how can the right not to know be harmonised with the potential interest of a patient’s relative in knowing?

As it has already been pointed out, some legal and ethical regulations try to give an answer to this difficult dilemma: the right not to know (like most rights) is not absolute because its exercise is conditioned by the fact that there is no risk of serious harm to other persons.\textsuperscript{25–27} That means that the disclosure to family members, if ever, could be accepted as an exceptional measure, as long as two conditions are fulfilled: firstly, the disclosure is necessary for avoiding a serious harm to them; secondly, some reasonable form of cure or therapy is available. However, we should not forget that we are dealing with unsolicited genetic information. We are indeed not sure that relatives really want to receive such information. This is why we should be extremely prudent before any unsolicited approach is made.

Those “other persons” that the exercise of the right not to know should not harm could be society in general. Public health interests may in particular circumstances justify limitations on the right to ignore one’s genetic make up as they may justify limitations to confidentiality, for instance, in the case of infectious diseases.\textsuperscript{28} Surely, the circumstances in which the right not to know and confidentiality can be breached in the interest of public health should be well defined by law. Particularly important in this context are population genetic screening programmes, which can contribute to the prevention of genetic diseases. For example, potential parents could be alerted to the risks they may take if they marry and have children with a person who also carries the genetic trait. However, such programmes face significant challenges in terms of informed consent, privacy, and risks of stigmatisation of ethnic groups. In addition, there is the fear that public screening programmes could encourage eugenic practices, like systematic abortion of affected fetuses.\textsuperscript{29} In summary, we have to make a substantial effort in this area to ensure an adequate balance between the respect for individuals’ rights and the benefits of using genetic information for the common good of society.

**The wish of not knowing should be explicit**

Graeme Laurie has argued that, in addition to “autonomy”, the right not to know might be based on a particular form of spatial privacy, the so called “psychological spatial privacy”, which encompasses separateness of the individual’s psyche. This aspect of spatial privacy tends to safeguard one’s own sense of the self and to provide a larger protection of the interest in not knowing than simple choice, especially in those cases in which no explicit choice has been made.\textsuperscript{30–32} Laurie’s concern is perfectly understandable: it is true that even if no wish has been expressed, the interest in not knowing can also be compromised by unsolicited revelations of genetic information. This circumstance leads the author to advocate a “prima facie” respect for the interest in not knowing, even in absence of an explicit choice.\textsuperscript{33} This means, in practice, an inversion of the burden of proof: it is not the person interested in not knowing who should express his or her wish but, on the contrary, it is the individual who intends
to disclose the information who, before any disclosure, should be sure that some special conditions are fulfilled (for example, the availability of a cure, the severity of the condition, the nature of the testing, and the question of how the individual might react if exposed to unwanted information). Therefore, this position “places the onus of justifying disclosure firmly on the shoulders of those who would do so.”

The appeal to privacy in order to call for an attitude of prudence in the disclosure of genetic information is fully justified, especially when there are doubts about the patient’s will. Moreover, the “privacy approach” provides an insightful explanation of what is at stake in this issue. It is true that when there is no previously expressed wish in respect of the information, the potential interference is primarily with the spatial privacy interests—or let’s say, with the psychological integrity—of the individuals in question, rather than with their autonomy per se.

However, what is difficult to accept in Laurie’s view is the assumption that those individuals who have not made any explicit choice of not knowing their genetic status (which means almost everybody) want to ignore it. In the case of competent patients, this assumption can hardly be harmonised with their “right to know,” as well as with the “duty to inform” that, in principle, the healthcare professional has towards them. Both competing rights—to know and not to know—cannot be the rule. Surely, to determine which right should prevail will depend on the circumstances of each case, but law and ethics need rules to operate in a coherent manner; and the rule in this field is that patients have a right to know their health status. This is why it seems that the right not to know may only be accepted as an exception, at least with regard to competent persons. The situation is probably different in the testing of minors, in which case genetic tests for adult onset genetic disorders should perhaps be simply banned, particularly when no cure is possible.

In brief, therefore, the argument of this paper is that the right not to know cannot be presumed, but should be “activated” by the explicit will of the person. Let us recall that, for those cases in which the interest in not knowing seems clear, but no explicit choice has been made, we already have the concept of “therapeutic privilege”, which allows physicians to withhold information if, based on sound subjective perceptions of the individual, who is, in fact, the best interpreter of his or her best interest. It should be noted that the problem of genetic tests is raised not so much by the information itself (which is neutral) but by the effect that that information may have on the person who has been tested. That effect varies greatly from individual to individual. This is why the previous informed consent should be as comprehensive as possible, in order to know in advance the patient’s interests and possible fears.

One could argue that this autonomy based approach is unrealistic, because it ignores the fact that people are not always free to decide according to their real interests. For instance, various forms of coercion, in a more or less subtle way, may lead individuals to choose to know their genetic make up, when in fact they would prefer to ignore it. The most obvious example is the requirement of genetic tests as a condition of employment or insurance. Nevertheless, the factual possibility of coercion in certain circumstances is not per se a sufficient reason to deny people the right to self determination regarding genetic information. It is true that coercion may happen in the field of genetic testing, but it may happen in all areas of clinical and research activities as well. If we consider that the likelihood of coercion is very high in certain circumstances, what we can do (as many ethical guidelines suggest) is simply to prohibit the requirement of genetic tests by insurance companies or employers and the requirement to disclose results of any previously undertaken genetic tests. Or at least we can put additional safeguards in place to ensure that people are free from coercion and are not exposed to unjustified discrimination. However, the risk of coercion should not lead us to deny that competent people, with appropriate genetic counselling, are in principle able to decide whether they want to know their genetic status or not.

Do third parties like patients’ relatives have a right not to know? In this case one has to recognise that such a right is even difficult to conceive. Firstly, for a practical reason: how can patients’ relatives exercise this right, if they probably even ignore that a family member has been tested? Moreover, against whom would they have this right? Against the doctor who, having tried to help them, disclosed that information? Against the family member who was tested and had revealed, for example at a family gathering, that he or she is at risk of a genetic illness? Would such a general “right not to know” not be a serious obstacle to confidence within the family? In addition to this, how can doctors assume that patients’ relatives do not have interest in knowing genetic information, which may be extremely important to them? Certainly, doctors should in principle avoid disclosing information about patients to individuals with whom they do not have any professional relationship.

Healthcare professionals have a duty of confidentiality towards their patients. But if in a particular case a doctor considers in good faith that he or she is morally obliged to disclose that information to patients’ relatives—for example, because a reasonable treatment or preventive measure is available—it would be an exaggeration to make him or her legally responsible on the basis of a supposed “right not to know” of those individuals. On the other hand, if there is no treatment or preventive measure for the disease, it is hard to imagine why healthcare professionals would be so interested in disclosing genetic information to patients’ relatives. If such a thing could come to happen, the doctor would be violating without justification his or her professional duties. However, we do not need to postulate that third parties have a “right not to know” their genetic make up, which would be an excessively strong argument, in order to protect them from unjustified invasions of their privacy.

One could theoretically imagine a solution to this complex dilemma with the creation of a “public register”—similar to those that exist for organ donation—where people can express in advance their wish to know or not know their genetic status. Of course, those who do not register a refusal would not be automatically presumed to be interested in knowing their genetic make up. The only purpose of such a register would be to give people a means to specify in advance their preferences concerning genetic information and, at the same time, to facilitate the task of doctors, who could consult the register before making any unsolicited disclosures. Nevertheless, for the moment we are still very far from a general solution of this kind. Therefore, it seems that at present the right not to know can only operate within the
The right not to know: an autonomy based approach

The right not to know: an autonomy based approach

CONCLUSION

The increasing access to genetic information leads law makers to recognise new rights in order to protect confidentiality and privacy of people. The “right not to know” is one of them. This claim is based on individuals’ autonomy and on their interest in not being psychologically harmed by the results of genetic tests. Such a right, as an exception to both the patient’s “right to know” and the doctor’s “duty to inform”, needs to be “activated” by the explicit will of the patient. In addition, this right has two characteristics: firstly, it can only operate in the context of the doctor-patient relationship; secondly, it is a relative right, in the sense that it may be restricted when disclosure to the individual is necessary in order to avoid serious harm to third parties, especially family members, which means that some form of prevention or treatment is available.

REFERENCES


A RESPONSE TO ANDORNO

Dr Andorno and I have corresponded for some time on the question of a right not to know (genetic) information. I enjoyed reading his paper and I am struck by the degree of agreement that we share. We both agree—for example, that unsolicited knowledge can be a burden which can significantly compromise an individual’s psychological integrity. We both share a desire to respect individual self-determination. Also we each consider it reasonable for individuals to choose not to receive potentially harmful information. I have already made these arguments, and more, elsewhere, but my starting point has not been autonomy, as advocated by Andorno, but rather privacy. In essence, my argument is that individuals enjoy, and are entitled to enjoy, a measure of psychological privacy which can be invaded by unwarranted disclosures of information (Laurie, pp 255–74).

The reason that I prefer privacy to autonomy is not because I have any wish to “deny people the right to self-determination” but rather because I perceive deficiencies in the autonomy model. Indeed, my approach and that of Andorno are not mutually exclusive; it is simply that my approach is broader and encompasses some of the harder cases which an autonomy based approach cannot help us to resolve. Thus, most of the substance of Andorno’s approach is subsumed within my model. I have—for example, no disagreement whatsoever with the view that if you have an indication that an individual would not wish to know then this wish should be respected. One might even establish novel means of discerning individuals’ wishes by establishing a register to record advance refusals, as Andorno suggests. What should happen, however, if there is no indication of an individual’s wishes? In such cases it is not possible to approach the individual to ask: do you want to know, because, as Fletcher and Werts poignantly observe: “There is...to exercise the choice of not knowing, because in the very process of asking ‘Do you want to know whether you are at risk’ the geneticist has already made the essence of the information known.”

If I have understood Andorno correctly, his model leaves this dilemma unresolved. His reluctance to adopt a broader approach stems, in part, from the charge that a decision not to disclose taken by a health care professional is paternalistic. To avoid this accusation, Andorno conceptualises his

www.jmedethics.com
“right not to know” as a means of *enhancement of autonomy*, whereby “the decision to know or not to know is not taken out of the hands of the patient by the doctor”. I have three observations about this approach. First, the patient-centred focus cannot answer the Fletcher/Wertz scenario. Second, paternalism is not a homogenous practice and not all forms of paternalism are bad.3 Paternalism has become a dirty word with the rise in success of the principle of respect for autonomy. The desire to enforce this principle now dominates much ethical and medicolegal discourse, but it is disingenuous at the same time to deny the presence of paternalism and, at times, the value of certain forms of it. Most particularly, it must be recognised that the autonomy model cannot provide ethical and legal solutions to all medical dilemmas and I would argue that we are misguided in trying to make it do so. Finally, there is an irony in Dr Andorno’s paper because not only does he recognise a role for paternalism at various junctures, but his argument about enhancement of autonomy, and his defence of conduct directed towards facilitating patient choices is, in itself, a form of paternalism. See—for example: “it is the responsibility of the health care professional to assess the amount of information an individual wants and is able to deal with at a particular time”. He also states: “…[l]et us recall that, for those cases in which the interest in not knowing seems clear, but no explicit choice has been made, we already have the concept of ‘therapeutic privilege’, which allows physicians to withhold information if, based on sound medical judgment, they believe that divulging the information would be harmful to a depressed or unstable patient...”.

He also asks “…how can doctors assume that patients’ relatives do not have an interest in knowing genetic information, which may be extremely important to them?”. I would respond that they cannot, nor should they. By the same token, I would add: how can health care professionals assume that relatives would wish to know? Once again, I would respond that they cannot do so. This is precisely the essence of the dilemma—a health care professional does not know one way or the other what relatives would or would not wish to know.

I do not assume that people do not want to know, as Dr Andorno suggests. Indeed, my position is quite the opposite. I challenge any assumptions about people’s wishes (Laurie,1 pp 257–61). I have, in fact, a serious concern about the current reoccurrence with autonomy and about its ascendency to the status of supreme ethical principle in many quarters. I question this on a number of grounds, not least because it is an incomplete answer to many dilemmas and because it leads to limitations on our thinking about how to approach ethical quandaries such as those posed by an interest in not knowing. The limits are expressed by Andorno himself when he states: “…the exercise of an autonomous choice seems necessary for the functioning of the right not to know, because it is impossible to determine a priori the wish of the patient”. The latter point may well be true, but Dr Andorno does not then go on to tell us how the harder cases should be dealt with where there is no prior indication of a patient’s wishes. His idea of a register is, as he himself admits, of limited utility and should not lead to an assumption that people would want to know. If one accepts that individuals can be harmed by unsolicited disclosures and that some protection for psychological integrity is desirable, it is difficult, then, to draw a meaningful distinction between those who have exercised their autonomy and so enjoy protection and those who have not done so and so fall outside the autonomy based approach.

My privacy model advocates that because we cannot assume anything about what people want in the absence of actual knowledge about their wishes then a measure of caution should be exercised in taking disclosure decisions. Various factors should be weighed in the balance before disclosure is made, including the availability of a therapy or cure, the nature of the disease and its consequences, and any advance statements made by the patient in question, if available (Laurie,1 pp 261–4). Most specifically, however, there should be recognition of an interest in not knowing. As Dr Andorno correctly identifies, this places the onus to demonstrate that some utility would come of the disclosure, on those who would seek to disclose. The presumption is that individuals’ psychological privacy should be respected unless there is good reason not to do so. Disclosures can be justified both in the interests of the individual herself and her relatives. Prior wishes should be respected but even in their absence a decision not to disclose may be reached to protect the individual’s privacy. This is undeniably a paternalistic approach; but the nature of the dilemma necessarily makes it so.

As a final caveat, I would question the use of the language of rights in this context. I myself am guilty of such usage, for it can often be a helpful form of shorthand in discussion. The details and implications of rights discourse sit uneasily, however, in the present circumstances, and for these reasons I agree with Dr Andorno that there should be no legal “right” not to know which can be enforced against family members (Laurie, p 265). A better approach, to my mind, is to talk of the *interest* that individuals might have in not knowing. On this basis, we might find that there is even less disagreement between myself and Dr Andorno.

**G Laurie**

Edinburgh Law School, University of Edinburgh, Old College, South Bridge, Edinburgh EH8 9YL, Scotland; graeme.laurie@ed.ac.uk

**REFERENCES**

The Roman Catholic Church and embryonic stem cells

Skene and Parker raise a number of concerns about religious doctrine unduly influencing law and public policy through amicus curiae contributions to civil litigation or direct lobbying of politicians. Oakley picks this up in his letter with an emphasis on the Roman Catholic Church's interest in preventing the destruction of embryos for embryonic stem cell research. Skene, Parker, and Oakley seem to be concerned mostly with religious views having undue influence on public policy. My concern is the negative effect that such Church influenced public policy may have on the progress of the biomedical research that is itself foundational to the debate. Oakley seems to be particularly incensed that, as he puts it: “Those who support a total ban on embryonic stem cell research sometimes talk as if theirs are the only views based on moral principle”. What seems to be at issue here though are not the moral principles of the sanctity and dignity of human life, but the application of those moral principles to biomedical research.

The Roman Catholic Church has historically defended the sanctity and dignity of human life to varying degrees at different times. Human life for much of the past 2000 years was defined by the Church as the presence of the soul, which was thought at different times to appear at various different stages during development. Only recently, with the advent of modern biology, has the Roman Catholic Church shifted its position to claim that the fertilised egg also qualifies as the right sort of human life. It should be noted that this doctrinal change was fundamentally driven by developments in our understanding of embryology and not the process of ensoulment. The Church's current position on the embryo is thus based not solely on Church doctrine but also on a specific interpretation of our empirical observations of human development. It is the Church's interpretation of the biology of early human development that is foundational to their current stand against experimentation on early embryos. However one of the reasons we may wish to experiment on early embryos is that we know surprisingly little about them. In fact any position that claims to be based on a solid, empirical understanding of the embryo is essentially misleading, as we simply do not have the data available. The reply to this will inevitably be that we know enough about embryos to make certain claims. For example the Roman Catholic Church likes to point out that the early embryo is obviously the earliest stage of a human life. Many would disagree with this on the grounds that the Church has confused being merely human with being a person. I am concerned by the claim that the early embryo is obviously the early stages of a human life. My concern is not that the claim isn't obvious to some people but that obviousness is a dangerous thing when it comes to science. It is, for example, quite obvious to me that I am currently sitting at my desk. Empirically my senses seem to confirm that I am more or less stationary. I may well believe that I am stationary. For much of human history we believed the earth to be stationary at the centre of the universe. This assumption was confirmed in the Western world by the Church itself. Church doctrine confirmed that the earth was the centre of the universe with the heavens above and hell below. When Galileo challenged this view by promoting the sun centred Copernican system of cosmology the Roman Catholic Church attempted to silence him. The Church's attack on Galileo and Copernicanism was tripartite. Firstly, the Copernican system appeared to contradict some scriptures. Secondly, the Copernican system threatened the Church's sanctioned science of the day represented by Aristotelian physics. Thirdly, was the appeal to obviousness or the immediate evidence of the senses. Of the three, only the scriptural objections were fundamental to the Roman Catholic Church's position. The appeals to science and obviousness were able to be settled by empirical evidence. We now know that we are not stationary at the centre of the universe although this is still far from obvious to many people.

Any position that claims to be based on a solid, empirical understanding of the embryo is misleading: we simply do not have the data.

The situation 400 years ago regarding Copernicanism thus seems to be very similar to that today regarding the status of the early embryo. The Roman Catholic Church tried to prevent Galileo from collecting empirical evidence using his telescope and disseminating his empirical evidence by banning his books. Similarly the Church today has attempted to prevent the gathering of empirical data on the early embryo by promoting a ban on all experimentation on early embryos. The Copernican revolution itself has become a paradigm for the process of theory change in science. Science is not simply a collection of results from experiments (or facts) but perhaps more importantly science is the interpretation of those results and the planning of further experiments. For all its claims of objectivity science is, so the philosophers of science tell us, essentially a theoretical construct. The practical and theoretical sides of science are of course intimately connected. In fact it is well known that a researcher's actions and observations are most likely guided to some degree by their own hopes and expectations. These same researchers develop the theories that they use to interpret their data. These theories fit the results (or facts) that have been previously observed and predict new experiments to be done. The role of theory at this stage of the process is often underestimated. Theories do not fall out of results. In fact in biology especially theories are often essential to making sense of whatcollected (result) and what is noise (artefact). Theory then is not just a bridge to the next fact or experiment but arguably the very heart and soul of science. Theories that do not fit the facts are of no use and should be discarded. But in biology especially, theories can define what counts as a fact and what does not. Sooner or later a startling new observation is made that cannot be accommodated within the existing theoretical framework. New theories are developed and past observations are re-categorised. What was written off as noise is heralded as fact. Thomas Kuhn called this paradigm shift and his paradigmatic case was the Copernican revolution. One overarching theoretical construct is replaced with another—our understanding of the world is literally changed forever.

A problem arises when an organisation such as the Roman Catholic Church erects its doctrinal structure on the shaky foundations of a specific theoretical construct. Biology and developmental biology in particular are comparatively young sciences that are progressing rapidly and are thus quite theoretically diverse. By lending its support to a certain theory or position within biology the Church may well be able to distort the natural balance that exists in science whereby theories are valued for their explanatory power or instrumental use, not their doctrinal compatibility. External interest groups with political lobbying power may thus hijack the academic process of progress in science with dire consequences for future advancement in science and medicine. The Roman Catholic Church's influence on science is indirect and is mediated through the medium of public opinion and public policy. As we have seen in the American debate over the status of the embryo with regards to the derivation of embryonic stem cells this influence may be decisive in the formation of public policy. Indeed President Bush's decision to effectively ban public funding of embryonic stem cell research in America is widely believed to have set back progress in the field worldwide by many years.

The Roman Catholic Church's input into the embryonic stem cell debate has not been simply moral or ethical as one might assume but has openly defended a particular claim about the biology of the early embryo. Given the basic lack of empirical evidence regarding the embryo and such developments as the unexpected properties of stem cells the Roman Catholic Church's choice of position on the biology of the embryo seems to be chosen solely as a prop for its doctrinal position. This prop has then been introduced into the secular debate on the status of the embryo as a somehow obvious empirical claim.

I believe the Church's religious fervour for its preferred doctrinal and scientific position of the day is fundamentally at odds with the process and progress of science. Science is an exploration of the physical world that is characterised by continual curiosity and, historically at least, major shifts in understanding. Over the last 400 years the Roman Catholic Church has been slow to accept that science progresses at all and has proceeded to maintain its doctrinal position as a matter of faith even when it has been shown to be empirically unsound. My concern here is I think similar to that of Skene...
and Parker. The Roman Catholic Church's contributions to public policy are based not only on their moral or ethical principles, but on an effectively arbitrary and dogmatic application of those principles that is backed by the full force of what is effectively a very powerful lobby group in many countries. Like Skene and Parker, I have no answer to the problem I have raised. Historically one thing is certain, in the future the Roman Catholic Church's current position on the embryo will be judged to have been right or wrong with the wisdom of hindsight. Just as we judge the Church's persecution of Galileo almost 400 years ago now.

P S Copland
PO Box 913, Dunedin, New Zealand;
ps@angler.otago.ac.nz

Accepted for publication 1 July 2003

References
1 Skene L, Parker M. The role of the church in deve-
2 O'Callaghan C. Ethics and law: The shift from
research, and the Roman Catholic church. J Med
Ethics 2002; 28: 228.
3 Pope John Paul II. The Gospel of Life [Evangelium
4 Copland P, Gillett G. The Bioethical Structure of a
5 Kuhn T. The Copernican Revolution: Cambridge:
Harvard University Press, 1957.
6 Stolberg S. Stereol research is slowed by
26 September 2002.

Non-compliance: a side effect of drug information leaflets

The problem of non-compliance with treat-
ment and its repercussions on the clinical evolu-
tion of different conditions has been widely
investigated.1 2 Non-compliance has also
been shown to have significant economic
implications, not only as a result of product
loss but also indirectly through the complica-
tion of disease management and its subse-
quent healthcare and social costs.3

Non-compliance as a health problem

The term “non-compliance” might be taken
to refer both to the failure to follow a drug
regimen and to the failure to adopt other
measures that contribute to improvement in
health—for example, changes in lifestyle or
diet. This letter focuses on the former.

Non-compliance with a drug regimen can be the
result of a number of different factors4 5 and a
variety of techniques have been developed in
an attempt to control it.6 7 Of these, the few
preferences that have been shown to be effective have only managed to solve the problem in specific situations over
short periods of time. The use of such
techniques to control non-compliance, particu-
larly where these are effective, raises
interesting ethical questions about the extent
to which their application constitutes an
infringement of the patient’s right to decide on
how to manage their own health.8 Here we
suggest that in some cases one factor that
leads to non-compliance is the tendency to
provide extensive and exhaustive information
on side effects in patient information leaflets.
Consider the following case.

A true story

One morning Dr Smith woke up with a slight
cold—muscular aches, headache, chills, and
nasal congestion. He decided to take some
medicine to counteract its effects. His initial
thought was to find something to combat his
runny nose, so he chose a product specially
indicated for nasal congestion: “StopSnot”.
After reading the product information leaflet,
however, Dr Smith felt another kind of chill
run down his spine. He was struck cold by
the contraindications, warnings, interactions,
precautionary measures, and contraindications
listed in the leaflet. If he used this drug, it said,
he would run the risk of suffering nausea,
anxiety, agitation, insomnia, hallucinations,
convulsions, amazement, weariness, arrhyth-
mania, dizziness… Rather than risk all of this,
he thought, why not suffer a few bothersome
snuffles? For his muscular aches, Dr Smith
chose another drug, “Abatache”, but the
risks described in the accompanying informa-
tion leaflet seemed even worse. These
included baldness, skin blistering, aspetic
meningitis, pneumonitis, fatal hepatitis,
gastrointestinal perforation, blood in the urine,
jaundice, kidney disease, peptic ulceration,
mouth ulceration, visual abnormality… So
in the end, armed with his clinical and
pharmacological knowledge, Dr Smith simply
opted to continue blowing his nose and suffer
a few muscular aches. He had no desire to
play Russian roulette with his health.

The principle of autonomy and the right to information

The principle of autonomy in medical ethics
places the patient at the centre of medical
decision making about his or her care. It
places particular emphasis on the importance
of informed consent, and suggests that,
except in rare situations,10 no patient should
undergo medical treatment or surgical inter-
vention without his or her fully informed
authorisation. This is the basis of patient-
centred medicine.

To obtain valid informed consent, it is
argued that the patient must receive suffi-
cient understandable information to make a
fully informed choice. In practice this means
that someone undergoing a specific treat-
ment receives information from at least two
sources. First they will be given direct
information from their doctor or another
health professional about the drug to be
taken, recommended lifestyle changes, and
perhaps a warning of the hazards related to
non-compliance. The patient will also be
provided with information on some of the
side effects attributed to the drug being
prescribed. Individual patients will tend to
understand this information in a range of
different ways, and it is well recognised that
they will respond with a variety of known
behaviour patterns.9

Secondly, the patient will also receive
additional information on side effects from
the information supplied with the

drug itself. These leaflets tend to cite each
and every one of the undesirable effects
related—note “related”—to the principle
active ingredient contained in the drug.
The information can in some cases be so
complete or detailed that even any extremely
unusual syndrome described in relation to the
use of the drug will inevitably be listed in the
leaflet as a possible side effect.5

This information can sometimes have a
significant effect on the likelihood that a
patient will take the drug in question and
may lead to significant “non-compliance”.5
When patients with minor ailments read
about all the problems that may occur from
using the prescribed medication, they may
start worrying, to say the least. Some people

read the leaflet again and again. They may
then consult another source of medical
information such as a website and perhaps
see contradicting evidence, whereby the
patient’s mindset is often a key element in the appearance of either
physical or imaginary side effects, as has been
shown in various studies.11 12 Such an effect
may be caused by information leaflets.

Complete information versus sufficient information

Practically any city dweller would refuse to
use transport services, work tools, or recrea-
tional facilities if they were supplied with
complete, absolute, and extensive informa-
tion on the hazards using these might entail.
Precautions and warnings are usually good
things, but they should be kept within
reasonable limits to avoid creating outright
alarm. Too much information can sometimes
undermine autonomy and also lead to sig-
nificant harms through non-compliance.

It was shown some years ago13 that
information supplied by doctors can generate
side effects that cannot subsequently be
corroborated by physical examination. As it
happens all too often, the information was
not as exhaustive or complete as it might be.
In view of this, we believe that the kind of
information given in drug descriptions
should be reassessed. The information should
be true, accurate, and easy to understand in
as complete a way as possible, but it should
generate alarm that can lead to deleteri-
ous consequences in the healthcare sector or
in the economic sphere.

So what did the patient decide?
The patient, shocked and dismayed at the
drug’s side effects, finally decides not to follow
the doctor’s recommendation. He (or she) will
try to relax, perhaps by smoking a cigarette
laced with nicotine, tar, and a number of other
substances. True enough, doctors recommend
giving up smoking. But who will listen to
what a doctor says about smoking when they
impose the requirement of taking drugs truly
hazardous to health? After all, a pack of cigarettes only says that

cigarette smoking seriously damages your
health. There is certainly no leaflet listing
every one of its possible side effects. Too
many, too complex, too unpalatable. Tobacco kills, but it sometimes looks as if
medication is worse.

F Verdu, A Castelló
Department of Legal Medicine, College of Medicine
and Odontology, University of Valencia, Valencia,
Spain

Correspondence to: Dr F Verdu, Department of Legal
Medicine, College of Medicine and Odontology,
University of Valencia E G, Av/ Blasco Ibáñez, n15,
46010-Valencia (Spain); Fernando.Verdu@uv.es

doi: 10.1136/jme.2003.003806

References
1 Morris AD, Boyle DI, McMahons AD, et al.
Adherence to insulin therapy, diet, and weight
control, and ketoacidosis in insulin-dependent
diabetes mellitus. The DARTS/MEMO Collaboration.
Diabetes Audit and Research in Tayside Scotland.
Diabet Med 1997; 14(5): 503–10
2 Bruckert E, Simonetta C, Giraud P. Compliance with
fluvastatin treatment characterization of the
noncompliant population within a population of
3845 patients with hyperlipidemia. CROELStudy

www.jmedethics.com

Response to ‘Patient organisations should also establish databanks on medical complications’

Gebhardt in his brief report1 pleads for patient organisations to establish databanks on medical complications. Given the references (for example, an article by Paans, a journalist, entitled “Medical errors to be kept secret”) and the second sentence—“Gebhardt claims that the substantial danger of misinterpretation of the current situation, which in turn may frustrate the process of increased transparency, is substantial,” which is a reference to resistance by the profession to respond to this by giving background information and reasons for some of the choices that were made with respect to the registry of complications mentioned by Gebhardt—First, a distinction needs to be made between an error and an adverse outcome, which are often confused. From Gebhardt’s reference to the journalist’s article which discusses the same registry of adverse outcomes, but with the title referring to errors, it becomes clear that the journalist thinks errors and adverse outcomes are the same thing. However, an error refers to the process in which something has gone wrong, a sub-standard performance, regardless of the outcome. It has been explained by others that such a judgement may have a degree of subjectivity.2 An adverse outcome refers to the outcome which is unwanted but does not necessarily imply that an error has been made. This is why the term “adverse outcomes” is used rather than the term “complications,” since the latter term is often confused with an error being made. The registration of medical complications that Gebhardt refers to is a register for adverse outcomes guided by an unambiguous definition of the term “adverse outcome,” of which only a small percentage is related to errors.3 Furthermore, some errors will be missed in this registration—that is, errors which have not led to adverse outcomes.

Secondly, with respect to confidentiality, this is relevant in particular for the initial years of such a registry during which it is thoroughly tested and accuracy of the registration may vary widely between participants. Nothing is gained by false positive signals with respect to the high incidence of adverse outcomes in some hospitals, except perhaps by flashing headlines in the newspapers. In this respect one may compare the development of such a national registry to the development of a new drug, in which case no one argues about confidentiality and thorough testing until proved safe. Moreover, a pharmaceutical company will probably be sued if it markets a new drug without proper research. It is intended that after this initial period, national adverse outcomes become available to the public with respect to probability of an adverse outcome given certain types of surgery.
Box 1: Patients need information to make a well informed choice

Who is a good doctor and what is a good hospital? This simple question is not easy to answer for doctors or patients who need a good diagnosis and the best treatment. The NPCF (Dutch Federation of Patients and Consumer Organisations) and its member organisations have published several consumer guides for specific diseases to help patients find their way in the labyrinth of the healthcare system. Patients experience many difficulties in getting access to relevant information from doctors' organisations and insurance companies. Therefore the NPCF wants to cooperate with these organisations to create consumer information based on the important and relevant data that are available. A joint project for a databank on best practices started in September 2003. Patients are not interested in black lists of doctors and malpractices, they prefer to know about good and best practices to make a well informed choice for a doctor or hospital. They need consumer information on objective measures such as the risk of infection in a hospital, the specific skills of a doctor, how many patients with this specific disease a doctor treats a year, etc. Patients would also like to receive subjective information on a specific hospital or doctor: How is the communication between a doctor and his or her patients? Does the team give enough information and support when needed?, etc. This experience based information is often available from patient organisations.

The NPCF has chosen to work together with organisations of healthcare providers and insurance companies to use parts of their databanks as a basis for consumer information. One task of the NPCF is to translate the data into consumer information that meets the needs of the patients, based on research and experiences of patients. Joint efforts are needed to make this important information accessible for doctors and patients.

Dr I van Bennekom, Director, NPCF

What do patients value in their hospital care? A response to Joffe et al

In the Journal of Medical Ethics, Joffe et al recently published an article titled "What do patients value in their hospital care? An empirical perspective on autonomy centred bioethics". This empirical study evaluates whether patients' willingness to recommend their hospital to others is more strongly associated with their belief that they were treated with respect and dignity than with their belief that they had an adequate say in their treatment." Joffe et al go on to suggest that confirmation of these empirical hypotheses would constitute a prescription for elevating the principle of respect for patients' perspectives they will be able to capture one side of this equilibrium, considered moral judgements or moral principles (they do not specify which), and in so doing contribute to the desired end: a consistent ethical framework to govern medical encounters, built (at least in part) from the moral principles and moral judgements that patients experience. Whatever the merits of this goal, however, Joffe et al fail to capture either the considered moral judgements or the moral principles of those they survey and so fail to contribute to the moral theory they seek to construct.

Ravels defines considered moral judgements as those judgements in which our moral capacities, which he considers analogous to our linguistic capacities, "are most likely to be displayed without distortion"—for example, those offered without hesitation, given without strong emotions like fear, and made in the absence of conflicting interests (p 47). The distinction considered judgements and judgements generally is important. When constructing a moral theory for a particular community—their theory of the patient community. Whatever the merits of this goal, however, Joffe et al fail to capture either the considered moral judgements or the moral principles of those they survey and so fail to contribute to the moral theory they seek to construct.

Finally, what does the patient want? (see box 1). International research has shown that patients do not use public information on performance of hospitals or doctors for making a choice of treatment or hospital because, among other reasons, they do not understand and do not trust these data. This also applies to adverse outcomes data. For interpreting the incidence of hospital specific adverse outcomes it is important to know the context—for example, since older, sicker, and more complex patients have higher probabilities of adverse outcomes. It is therefore vital to establish a reliable registry which can be trusted and understood both by medical professionals and the public. For this reason, the Association of Surgeons of the Netherlands and the Dutch Federation of Patients and Consumer Organisations (NPCF) are collaborating with respect to the national surgical adverse outcome registry, in particular, to produce information that is relevant for patients about treatment and hospital choices. Supported by the international literature, the NPCF holds the view that patients are not primarily interested in data on adverse outcomes, since they are aware that these data need to be interpreted in the right context. Patients are more interested in the experience of doctors or hospitals to treat certain diseases or to perform certain operations, since the question they want answered is "What is the best place to go to for this type of problem?". That this doctor or hospital probably has a high adverse outcome record is not relevant, since this may well be explained by the complex patients who are referred to more experienced doctors. As argued in a previous paper, it is essential that there is an increased mutual trust between the medical profession and patients' organisations that supports a combined effort to improve the quality and availability of patient information. Such initiatives involve both medical doctors and doctors and are too important to be frustrated by references to "powers that must be kept under control".

P J Marang-van de Mheen
Association of Surgeons in the Netherlands, the Netherlands

J Kievit
Department of Medical Decision Making, Leiden University Medical Centre, Leiden, the Netherlands

Correspondence to: Dr P J Marang-van de Mheen, Association of Surgeons in the Netherlands; p.j.marang@lumc.nl
doi: 10.1136/jme.2003.005850

References

www.jmedethics.com
Although it is difficult to give a positive answer to these questions (and I will not attempt to do so here), some survey methods, such as the mailed questionnaires that Joffe et al used, seem particularly inadequate. Rawls suggests that certain external conditions favour the formation of considered judgements: “the person making the [considered] judgment is presumed to have the ability, the opportunity and the desire to reach a correct decision (or at least, not the desire not to)” (p 48). Very likely, however, many of Joffe et al’s respondents lacked the necessary ability, opportunity, or desire to develop their moral judgements when responding to the questionnaire they received in the mail. Furthermore, even if a number of patients did offer legitimate considered judgements, there is no way to distinguish these from those made by respondents who lacked the requisite ability or desire. Although the size of Joffe et al’s study is of value for its ability more accurately to reflect a population’s response to its survey, because of the practical limitations that its size produces: does this survey really address what we mean by the principles of respect for autonomy and respect for patients?

With any empirical study in bioethics, there is a gap between the empirical hypotheses the study confirms and the normative conclusions its authors would like to draw from it. In their article Joffe et al hoped to bridge this gap by invoking Rawls’s notion of the reflective equilibrium. As I have explored, however, the study does not contribute to either side of the reflective equilibrium they imply, and, thus, they fail to demonstrate how their findings challenge the centrality of autonomy and shared decision making in bioethics.

Joffe et al’s failures are instructive, however, insofar as they suggest how we could better bridge the gap between research and theory. The use of the reflective equilibrium in empirical research has promise, provided researchers are clear about: (1) how to define considered moral judgements and/or principles; (2) how their methods capture these judgements and/or principles reliably; (3) how the inclusion of considered moral judgements strengthens rather than weakens bioethical theory; and (4) how their findings are valid for the judgements or principles they mean to assess. In addition, empirical research can contribute to bioethics by questioning the assumptions implicit or explicit in our normative views. Joffe et al try to do just this when they argue in the introduction to their article (p 103) that patients’ desire to delegate decision making challenges the mandatory autonomy view. However, if empirical findings are to defeat a particular normative principle, the assumption that those findings challenge must be logically necessary for our holding that principle. For instance, without showing that patients’ desire for autonomy is necessary for our holding the mandatory autonomy view, the studies that Joffe et al cite, even if valid, can be interpreted variously as devaluing the mandatory autonomy view or as recommending that we better educate patients on the value of autonomy. This normative question cannot be settled empirically.

Empirical researchers have the potential to contribute substantially to bioethics, but their work needs the kind of overhead and empirical rigor that comes from truly interdisciplinary collaboration and must be informed by a careful reflection on the proper relationship between descriptive and normative ethics. Joffe et al take us part of the way down that path. An exciting research itinerary lies ahead.

References


D P Narendra

1127 Nielsen Court, Apt. 4, Ann Arbor, MI 48105, USA; dnanrend@med.umich.edu

doi: 10.1136/jme.2003.005892

Received 18 July 2003
In revised form 20 October 2003
Accepted for publication 21 October 2003
How to be a ‘good’ medical student

The public revelation in 2003 that medical students perform intimate examinations without patient consent has engendered much debate in the press and scientific journals. Using this case as a springboard for discussion, I will argue that medical schools should encourage students to raise their ethical concerns and call for a change in policy making it easier for students to do so. I will also address the question of medical students’ moral obligations towards their patients. I conclude that medical students ought to express their discontent when faced with unethical practices or attitudes.

In early January 2003, a study appeared in the British Medical Journal revealing that nearly a quarter of rectal and vaginal examinations on anaesthetised patients were performed by medical students without patient consent. Although the study did not generate the firestorm of controversy many expected, it engendered much discussion on ethical issues surrounding informed consent and patient autonomy, as well as stressing the need for greater ethics training for medical students. As an ethical problem, the case of intimate examinations—teaching tomorrow’s doctors—could itself engender much discussion on the ethical and practice issues surrounding it.

Judging from some of the comments from students at Bristol, however, the growing emergence of medical ethics has not dispelled the awkward climate of unquestioned reverence towards teachers. Many of the students felt uneasy about the examinations, but were too intimidated to voice their concerns: ‘You couldn’t refuse comfortably. It would be very awkward, and you’d be made to feel inadequate and stupid’, commented a fourth year student who participated in the study. It seems clear that medical schools should strive to foster a climate more conducive to open discussion on ethical issues between students and teachers. Students should not have to perform heroic acts of courage to raise ethical concerns. In light of medical ethics’ place in the curriculum, the situation is deeply paradoxical. Students may be taught the importance of respecting the patient’s autonomy one day, but witness an obvious violation of this principle by their teachers the next. For the subject to be of any use, students must not only be allowed, but positively encouraged to put into practice their knowledge without the fear of appearing ‘inadequate and stupid’. If a student’s ethical concerns remain unresolved after discussion with the teacher, there should be a formal mechanism of complaint, perhaps through a committee specifically set up for the purpose, or through the school’s medical ethicist, who would then investigate the matter thoroughly. Medical ethics is, after all, an applied discipline.

It is nonetheless all too easy to blame the medical establishment and individual teachers for the unethical behaviour of students, as if the apocryphal ‘medical student’ shielded individual patients from moral fault. In Nick Hornby’s novel “How to be good”, the narrator, an adulterous GP and mother of two, resolutions her moral comumdrums by mechanically repeating “I must be good. I’m a doctor”. It is only later that she acknowledges that her justification is too facile: “It’s not enough to just be a doctor, you have to be a good doctor”. Students, however wide eyed or intimidated by an unlikely scenario in a commentary on Dr Coldicott’s study, Brittinger Nesheim, a professor of obstetrics and gynaecology in Norway, affirms that obtaining patient consent to student examinations is not difficult as long as the patient feels comfortable with the arrangements. Yet for me the study raises a more interesting question which extends beyond the recondite sphere of intimate examinations. It concerns the moral obligations of medical students faced with ethically dubious situations. In short, what should a “good” medical student do?

In an article on the scope of medical ethics, Professor Raanan Gillon recounts two experiences from his days as a medical student. The first describes his teacher’s refusal to grant an abortion to a 14 year old girl on the grounds that she was “a slut”; the second his own refusal to examine a scrotal lump on a patient whose testicles had already been examined by five other students. Gillon’s objections were very much the exception. When these events took place in the 1960s, medical students were simply expected to follow their teachers’ orders and to absorb their evident wisdom without question. Since then, medical ethics has developed from an ill defined embryonic subject to an academic discipline in its own right, with specific journals and associations, and a place in the medical curriculum.

References

2. Gillon R. Prospective and retrospective respecting the patient’s integrity is the key. BMJ 2003;326:100.

Acknowledgements

The author thanks Raanan Gillon, George Freeman, Richard Ashcroft, and Anna Smajdar for their helpful comments and suggestions.

D K Sokol
Medical Ethics Unit, Department of Primary Health Care & General Practice, Imperial College School of Medicine, London W6 8RF, UK; daniel.sokol@imperial.ac.uk

NOTICES

JME editorial office has now moved

The JME editorial office has now moved to BMA House. The new contact details are: Journal of Medical Ethics, BMA House, Tavistock Square, London WC1H 9JR. Tel: +44 (0) 207 383 6439. Fax: +44 (0) 207 383 6668. The point of contact is Nayanah Siva, Editorial Assistant.

Institute of Medical Ethics Medical Student Electives

The JME wishes to award 10 bursaries of up to £500 each to support Medical Student Electives, or exceptionally Special Study Modules, on issues in medical ethics.

Medical students, jointly with their supervisor, are invited to apply by 28th February 2005. Application is to be done via email, explaining the project’s relevance to medical ethics and the reasons why a bursary is requested. An outline study protocol and project budget should be included or attached. Applications should be sent to Mrs M Bannatyne, JME Bursaries Administrator, email: bannatyne@dial.pipex.com.

Successful applicants will be informed by 31st March 2005.

Correction

doi: 10.1136/jme.2002.001578corr1

An error has been pointed out in the affiliation for R Andorno, author of The Right not to know: an autonomy approach (J Med Ethics 2004;30:435–439). The correct affiliation is: Interdepartmental Center for Ethics in the Sciences and Humanities (IZEW), University of Tübingen, Tübingen, Germany. The journal apologises for this error.